Proactive Investors - Run By Investors For Investors

Proactive Investors One2One Investor Forum - London

Alliance Pharma plc | IXICO PLC | Benchmark Holdings PLC | Clinigen Group PLC | Shield Therapeutics PLC

The presentations will start at 6:00pm and finish at approx 8:00pm. After the presentations are complete the directors will also be available to take questions during a free canapé and wine reception. Details on the presenting companies can be found below.

 

This event is suitable for the following:

Sophisticated & private investors, private client brokers, fund managers, financial institutions, hedge funds, buy & sell side analysts and journalists.

 

The event is not suitable for people pursuing commercial opportunities.

Alliance Pharma plc

RSS Portfolio

Alliance-logo.png


Alliance is an international publicly owned pharmaceutical group listed on AIM, part of the London Stock Exchange. It was founded in 1998 and has its headquarters in the UK.

Alliance's principal activities are the acquisition and licensing of mature pharmaceutical products and the marketing of those products. Its manufacturing, storage, logistics and sales forces are controlled by Alliance but outsourced to leading specialist organisations in these fields.

Our expertise lies in the acquisition and licensing of pharmaceutical and healthcare products and delivering these to patients. We look carefully for certain criteria in these products and select for a blend of underlying sales stability and growth potential.

EPIC: APH
Market: ISE
52-week High/Low: 102.500p / 58.000p
Market Cap: 347.13M


View full company profile

Benchmark Holdings PLC

RSS Portfolio

1543922402_BMK-Secondary-Black.png


DRIVING SUSTAINABILITY IN FOOD PRODUCTION

Benchmark is a leading provider of aquaculture solutions in genetics, health and specialist nutrition. Our focus is on developing innovative products that help fish and shrimp producers improve their sustainability and profitability by improving yield, quality, and by reducing mortality. Our main products are salmon eggs with superior genetic traits, specialist nutrition products for shrimp and fish, and health treatments including a sea lice treatment for salmon. We serve all the major aquaculture markets around the world and have leading market positions. Benchmark operates in 27 countries, employs 1,066 people and reported revenues of £140m in 2017.

EPIC: BMK
Market: AIM
52-week High/Low: 81.000p / 48.000p
Market Cap: 328.92M


View full company profile

Clinigen Group PLC

RSS Portfolio

1519730732_Clinigen.png


Clinigen Group plc is a rapidly-growing global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time to improve the quality of people's lives around the world. The Group consists of three synergistic operations focused in three areas of global medicine supply; clinical trial, unlicensed and licensed medicines.

The Group was formed in 2010 and joined AIM in 2012 and since has delivered strong shareholder returns with a more than six-fold uplift in market cap, which today is over £1bn, making it one of the biggest companies on AIM.
Within the past three years, the Group has made three large corporate acquisitions doubling the size of the business and increasing its geographical footprint.

 

EPIC: CLIN
Market: ISE
52-week High/Low: 1,116.000p / 777.000p
Market Cap: 1,099.19M


View full company profile

IXICO PLC

RSS Portfolio

ixico-logo.png


IXICO is dedicated to delivering insights in neuroscience. The company's mission is to transform the advancement of investigational therapies for neurological diseases through the application of medical image analysis and digital health technologies, bringing safe and effective treatment to patients sooner. 

IXICO’s digital platform and Artificial Intelligence (AI) software are used by the global pharmaceutical industry to collate and interpret brain scan data from MRI and positron emission tomography (PET) scanners, as well as making sense of real world data collected using wearable biosensors. IXICO's specialist data analytics services extract biomarkers from brain scan and wearable biosensor data to enable better patient selection, quantification of disease progression and assessment of patient outcomes.

IXICO provides technology-enabled services across all clinical trial phases as well as in post marketing surveillance, and our integrated digital platform provides a scalable and secure infrastructure to manage the standardisation, capture and analysis of regulatory compliant clinical data.  The company's neuroimaging and digital biomarkers are powering some of the most important clinical trials in neuroscience today, enabling our clients to design better trials and make rapid, better informed assessments of drugs safety and efficacy.  IXICO is also collaborating with partners to develop new analytical techniques and companion digital health products targeted at improving patient outcomes.
 

EPIC: IXI
Market: AIM
52-week High/Low: 4,266.070p / 18.780p
Market Cap: 10.06M


View full company profile

Shield Therapeutics PLC

RSS Portfolio

1544002920_SHIELD_THERAPEUTICS_PLC_IMPROVING_COLOUR_LOGO.jpg


Shield Therapeutics is a high potential, commercial stage specialty-pharma company. We pride ourselves on providing solutions to unmet medical needs and delivering value to our shareholders.

EPIC: STX
Market: LSE
52-week High/Low: 115.000p / 14.000p
Market Cap: 36.56M


View full company profile

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use